Overview

• U.S. cancer immunotherapy developer posted Q1 net loss, reversing prior-year net profit

• Company ended Q1 with $194.8 mln cash, expects runway into Q1 2028

Outlook

• Company expects cash position to fund operations into Q1 2028

Result Drivers

• R&D SPENDING - Higher clinical trial and manufacturing costs for aglatimagene programs drove increased research and development expenses

• COMMERCIAL READINESS - Higher commercial readiness costs and increased employee expenses raised general and administrative expenses

Company press release: ID:nGNX1ymr59

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Candel Therapeutics Inc is $19.50, about 118.1% above its May 13 closing price of $8.94

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.